^
    Back
    Association details:
    Biomarker:MLL-AFF1 fusion
    Cancer:Acute Lymphocytic Leukemia
    Drug:ONX 0914 (Immunoproteasome inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Sci Rep
    Title:

    Activity of immunoproteasome inhibitor ONX-0914 in acute lymphoblastic leukemia expressing MLL-AF4 fusion protein

    Published date:
    05/25/2021
    Excerpt:
    We found that MLL-AF4 cells express high levels of lymphoid tissue-specific immunoproteasomes and are sensitive to pharmacologically relevant concentrations of specific immunoproteasome inhibitor ONX-0914, even in the presence of stromal cells.
    DOI:
    10.1038/s41598-021-90451-9
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    AACR 2020
    Title:

    Abstract 1936: Immunoproteasome inhibitors for the treatment of ALL

    Published date:
    06/23/2020
    Excerpt:
    Cells with MLL-AF4 translocations were sensitive to pharmacologically relevant concentrations of specific immunoproteasome inhibitor ONX-0914 . Furthermore, ONX-0914 dramatically delayed growth of orthotopic xenograft tumors in mice.
    DOI:
    10.1158/1538-7445.AM2020-1936